Abstract
The pathogenesis and progression of breast cancer involve complex interactions between hormones and polypeptide growth factors such as insulin-like growth factor-I (IGF-I). IGF-I has been found in stromal fibroblasts derived from malignant and benign breast tissue and it is a mitogen for several breast cancer cell lines. It circulates bound to specific high-affinity binding proteins, which could act as either positive or negative modulators of tumorigenesis. This study has been addressed to characterize IGF-I and its binding proteins in the serum of 85 unselected patients with early breast cancer. The IGF-I concentration was assessed by radioimmunoassay of 69 out 85 samples before and after dissociation of the IGF-I and IGF-binding protein (IGF-BP) complex whereas IGF-BP of all 85 sera were analyzed by Western ligand blotting; estradiol and progesterone were measured by radioimmunoassay in native serum samples. In our study no differences in IGF-I serum levels between pre- and post-menopausal patients were observed. Patients with higher estradiol and progesterone serum levels did not present different IGF-I concentrations compared to patients with lower serum levels. Furthermore, IGF-I median values were not found to depend on estrogen receptor (ER) status. A heterogeneous quali-quantitative molecular pattern of binding proteins was detected: IGF-BP3 and IGF-BP1 were the most and the least expressed respectively. No correlations between ER status, or parameters related to the hormonal status, and IGF-I or binding proteins expression were observed. No significant differences in IGF-I concentration and IGF-BP expression were observed between cancer patients and a control group matched for age and menopausal status. Finally, preliminary collection of 20 sera derived from patients with late breast cancer was analyzed for IGF-I and its binding proteins content.
Similar content being viewed by others
Abbreviations
- IGF :
-
insulin-like growth factor
- BP :
-
binding protein
- ER :
-
estrogen receptor
- RIA :
-
radio-immunoassay
References
Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, Osborne CK (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418–1423
Barreca A, Minuto F (1989) Somatomedins: chemical and functional characteristics of the different molecular forms. J Endocrinol Invest 12:279–293
Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS (1988) Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543–555
Baxter RC, Martin JL (1989) Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res 1:49–68
Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR (1989) Insulin-like growth factor I (IGF-I) binding protein complex is a better mitogen than free IGF-I. Endocrinology 125:766–772
Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson NE, Dickson RB, Lippman ME (1987) Synthesis and secretion of platelet-derived growht factor by human breast cancer cell lines. Proc Natl Acad Sci USA 84:5763–5767
Campbell PG, Novak JF (1991) Insulin-like growth factor binding protein (IGFBP) inhibits IGF action on human osteosarcoma cells. J Cell Physiol 149:293–300
Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK (1990) Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 127:2679–2686
Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME (1991) Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51:4978–4985
Daughaday WH (1987) Radioligand assay for insulin-like growth factor II. In: Methods Enzymol 146:248–259
De Mellow JSM, Baxter RL (1988) Growth hormone-dependent insulin-like growth factor (IGF) binding proteins inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 156:199–204
Dickson RB, Lippman ME (1987) Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrinol Rev 8:29–43
Dickson RB, McManaway ME, Lippman ME (1986) Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 232:1540–1543
Drop SL, Kortleve DJ, Guyda HJ (1984) Immunoassay of a somatomedin-binding protein from human amniotic fluid: levels in fetal, neonatal and adult sera. J Clin Endocrinol Metab 59:908–915
Elgin RG, Busby WH, Clemmons DR (1987) An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 84:3254–3258
Favoni RE, Cupis A de, Ravera F, Cantoni C, Pirani P, Ardizzoni A, Noonan D, Biassoni R (1994) Expression and function of the insulin-like growth factor I system in human normal lung and non-small cell lung cancer cell lines. Int J Cancer 56:858–866
Figueroa JA, Yee D (1992) The insulin-like growth factor binding proteins (IGF-BPs) in human breast cancer. Breast Cancer Res Treat 22:81–90
Furlanetto RW, Marino JM (1987) Radioimmuno-assay of somatomedin C/insulin-like growth factor I. Methods Enzimol 146A:216–226
Hardouin S, Hossenlop P, Segovia B, Seurin D, Portolan G, Lassarre C, Binoux M (1987) Heterogeneity of insulin-like growth factor binding proteins and relationship between structure and affinity I. Circulating forms in man. Eur J Biochem 170:121–132
Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M (1986) Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 154:138–143
Klapper DG, Svoboda ME, Van Wyk JJ (1983) Sequence analysis of somatomedin-C: conformation of identity with insulin-like growth factor I. Endocrinology 112:2215–2217
Krywicki RF, Yee D (1992) The insulin-like growth factor family of ligands, receptors and binding proteins. Breast Cancer Res Treat 22:7–19
Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65:311–320
Osborne CK, Arteaga CL (1990) Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat 15:3–11
Osborne CK, Coronado E, Kitten LJ, Arteaga CL, Fuqua SAW, Ramasharma K, Marshall M, Li CH (1989) Insulin-like growth factor II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via IGF-I receptor. Mol Endocrinol 3:1701–1709
Papa V, Hartmann KKP, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID (1991) Progestins induce down regulation of insulin-like growth factor I (IGF-I) receptors in human breast cancer cells: potential autocrine role of IGF II. Mol Endocrinol 5:709–717
Pekonen F, Partanen S, Makinen T (1988) Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroids receptors in human breast cancer. Cancer Res 48:1343–1347
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A (1993) Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 29:492–497
Pollak MN, Polychronakos C, Yousefi S, Richard M (1988) Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154:326–331
Pollak M, Huynh H, Lefebvre SP (1992) Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22:91–100
Reeve JC, Payne JA, Bleeben NM (1990) Production of immunoreactive insulin-like growth factor I (IGF-I) and IGF-I binding proteins by human lung tumors. Br J Cancer 61: 727–731
Rosenfield RI, Furlanetto R, Bock D (1983) Relationship of somatomedin-C concentrations to pubertal changes. J Pediatr 103:723–728
Rudman D, Feller AG, Nagraj HS, Gergan GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE (1990) Effects of human growth hormone in men over 60 years old. N Engl J Med 323:1–6
Scott CD, Martin JL, Baxter RC (1985) Rat hepatocyte insulin-like growth factor I and binding protein: effect of growth hormone “in vitro” and “in vivo”. Endocrinology 116:1102–1107
Shimasaki S, Ling N (1991) Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1,-2,-3,-4,-5 and-6). In: Prog Growth Factor Res 3:243–266
Sporn MB, Roberts AB (1985) Autocrine, paracrine and endocrine mechanisms of growth control. Cancer Surv 4:627–632
Stewart AJ, Johnson MD, May FE, Westley BR (1990) Role of insulin-like growth factor and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172–21178
Swain S, Dickson RB, Lippman ME (1986) Anchorage independent epithelial colony stimulating activity in human breast cancer cell lines (abstract). In: Magee PN (ed) Proceedings of the Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, Waverly Press, Baltimore, p 213
Topper YJ, Freeman CS (1990) Multiple hormone interaction in the development biology of the mammary gland. Physiol Rev 60:1049–1115
Vorherr H (1990) (ed) Breast cancer. Urban & Schwarzenberg, Baltimore
Yee D, Favoni RE, Lippman ME, Powell DR (1991) Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat 18:3–10
Zapf J, Froesch ER (1986) Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Horm Res 24:121–130
Author information
Authors and Affiliations
Additional information
This study was partially supported by a grant to R. E. Favoni from the Associazione Italiana per la Riecerca sul Cancro (A.I.R.C.), Milan, Italy, which also supported A. de Cupis
Rights and permissions
About this article
Cite this article
Favoni, R.E., de Cupis, A., Perrotta, A. et al. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status. J Cancer Res Clin Oncol 121, 674–682 (1995). https://doi.org/10.1007/BF01218526
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01218526